Table 2 Treatment data and efficacy of GEMCIS in unresectable gallbladder cancer
Variables | N = 173 |
|---|---|
Treatment duration, months | 3.8 ± 3.9 |
Total cycle | 5.3 ± 4.4 |
OS, months (95% CI) | 8.1 (7.1–10.2) |
PFS, months (95% CI) | 5.6 (4.5–6.8) |
Best response | |
 CR | 2 (1.2%) |
 PR | 26 (15.0%) |
 SD | 75 (43.4%) |
 PD | 48 (27.7%) |
 NE | 22 (12.7%) |
ORR (CR + PR) | 28 (16.2%) |
DCR (CR + PR + SD) | 103 (59.5%) |
Number of cycles | |
 1 | 38 (22.0%) |
 2 | 31 (18.0%) |
 3 | 8 (4.7%) |
 4 | 16 (9.3%) |
 5 | 10 (5.8%) |
 6 | 18 (10.5%) |
 7 | 6 (3.5%) |
 8 | 14 (8.1%) |
 9 | 2 (1.2%) |
  ≥ 10 | 30 (17.4%) |